Cell Biology Treatment Trials 
Drug Target Review
NOVEMBER 17, 2023
The relative ease and lower cost of manufacture (potentially a few thousand dollars) compared to autologous T cell therapies (hundreds of thousands of dollars), coupled with their functional attributes and safety profile, make NK cells an attractive therapeutic option for cancer patients, but surprisingly this is not universally recognised.
Drug Target Review
MARCH 3, 2025
The search for effective treatments for neurodegenerative diseases like Parkinson’s disease has long been hindered by the brain’s complexity and the absence of adequate models for drug discovery. This approach has the potential to revolutionise clinical trial design and lead to more effective, personalised treatments.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Target Review
JUNE 7, 2024
The proof for this came with the approval of KIMMTRAK (tebentafusp-tebn) by the FDA in 2022 for the treatment of HLA-A*02:01+ metastatic or unresectable uveal melanoma, a historically “cold” tumour known to be resistant to current available checkpoint immunotherapies.
Drug Target Review
AUGUST 24, 2023
We will explore how GDF-15 impacts the tumour microenvironment and hinders the infiltration of T cells into the tumour, as well as the implications of neutralising GDF-15 to reverse its inhibitory effects and sensitise tumours to anti-PD-1 treatment. T-cell infiltration is a prerequisite for responses to checkpoint inhibitors.
Drug Target Review
OCTOBER 31, 2023
When I was studying cell biology, looking at how cells divide, I couldn’t fathom how math could possibly fit into that. My undergraduate studies focused on biochemistry and cell biology, so very much STEM-based, but my professors and mentors noticed my penchant for critical thinking which led me to consider law.
The Pharma Data
OCTOBER 22, 2020
Monalizumab, Innate’s lead partnered asset, is a potentially first-in-class immune checkpoint inhibitor targeting NKG2A receptors expressed on tumor infiltrating cytotoxic CD8+ T cells and NK cells. Dosing of the first patient in this trial has triggered a $50 million milestone payment from AstraZeneca to Innate. “W
DrugBank
JUNE 27, 2023
The general notion is that patients should be viewed individually, rather than strictly as members of some larger general population, and that their specific genetic background, environment, and lifestyle choices should be considered throughout drug development to the point of treatment and continuing patient care.
Expert insights. Personalized for you.
118 
Let's personalize your content